Drug Panorama Issue No.4,

List Of Contents

   

Essential Drugs Concept : Time for the Developing Countries to Wake Up !

Sexually Transmitted Diseases in Women: A case for Syndromic management

Genital Ulcers Vaginal Discharge Lower Abdominal Pain (LAP) Inguinal Bubo

Adverse Drug Reactions Scan

Drug Policy Issues : The goal of a National Drug Policy
 
 

 

 

Essential Drug Concept: Time for the Developing countries to wake up !

go top

 

The WHO defines "Essential drugs as those which satisfy the health care needs of the majority of the population; they should therefore be available at all times in adequate amounts and in the appropriate dosage forms."

The goal for health for all has been approached in many countries through strengthening of primary health care. Providing this network of dispensaries with regular supplies of quality drugs to treat the most common health conditions is perhaps the most important factor, which boosts the confidence of the population in the health care delivery system.

It is not a simple matter to ensure the availability of safe, affordable essential drugs. Legislations, technical and medical logistic skills of an advanced nature are needed for ensuring supplies. Pharmaceutical companies market their products with little concern for the different health needs or priorities of a country and they fuel demand by manufacturing and selling non-essential drugs like latest antibiotics, tranquilizers, tonics most with no proven therapeutic value.

Developing countries cannot afford to waste their resources on the luxury of non-essential drugs Pharmaceutical companies perceive the vast potential of these countries in terms of the sheer size of the population and laxity of rules. These countries are therefore considered ideal for selling their high priced, non-essential formulations with a consequent burden on the individual.

In the interest of social justice and health, out of which the concept of essential drugs was born, it is time that the principle is adopted by all developing countries. They should draw up their priorities, develop national drug policies and thus ensure access of quality medicines to all.

 

 

Sexually Transmitted Diseases in Women: A case for Syndromic Management

go top

 

STDs are a public health problem, Reproductive Tract Infections are compounded by complications of STD and can result in primary and secondary infertility, poor pregnancy outcomes such as abortions, pre-terry delivery, malformations and congenital STDS. In addition these diseases can cause stress and marital problems.

While studies have been done to find out the extent of the problem, these cannot describe the personal anguish and harm that such diseases can cause to women. These research findings urgently need to be translated into policy and used to raise awareness about these diseases among women and men. Most women diagnosed with an STD are symptomless they only find out they are infected when tested at a clinic for another reason usually for ante-natal and family planning services. This fact is emphasized by a study in which women from twelve different African countries attending ante-natal clinics were screened for STDs and were found to have syphilis at rates varying from 2-33%. The effect of STDs on pregnancy associated conditions is severe. STD infection while pregnant can lead to stillbirth, pre-mature birth, post partum pelvic inflammatory disease, eye impairment in the new-born and perinatal AIDS.

In order to deal with the serious problem of STDs in pregnant women it is important to at least carry out syphilis screening at ante-natal clinics and provide prompt treatment to protect the mother, baby and the sexual partner(s). STDs have a negative effect on women's fertility although the actual number of women who become infertile due to STDs is not known. Female commercial sex workers are even more at risk of contracting STDs than other women. This is because they have multiple sexual partners and condom use is low.

The high rate of various types of infections among CSW cannot be over-emphasised because these workers are part of society and interact with the male population, locally, nationally and internationally. During this decade research on relationship and other STDs has revealed that sexual transmission of HIV may be facilitated by the presence of STDS, this may partly be an explanation of varying HIV rates around the world. HIV infection and consequent immunodeficiency may alter the progress of the disease, diagnosis or response to other STD treatment. STDs may influence the natural progression of HIV by accelerating the progression of clinical disease. HIV infection may also increase the susceptibility to other STDs.

In India according to a baseline study conducted in l992,in a red light area in Calcutta 59% of the CSWs were found to have STDs. In Madras the VDRL positivity was as high as 10% in female remand prisoners and the rate among women attending antenatal clinics 1.74%. In a population based cross-sectional study in rural Maharashtra 92% of all women surveyed were found to have one or more gynaecological problems. Infections of the genital tract (vaginitis cervicitis and PID) contributed to half of thin morbidity.

The fundamental goal of STD control programmes is early detection and treatment of the disease preferably at the point of patient's first contact with the health system. The syndrome approach to STD case management uses common symptom complex of STD as a starting point and to treat and counsel about STD prevention and partner notification. Condom provision is an essential part of syndromic management. Besides being simple and inexpensive syndromic case management allows for diagnosis and treatment in a single visit. Standardisation of treatment regimens is of paramount importance as they facilitate training and supervision, delay the development of antimicrobial resistance in sexually transmitted agents such as N.gonorrhoez and H. ducreyi and most importantly, rationalise the procurement of drugs.

 

 

 

GENITAL ULCERS  

go top

The chart below gives the treatment path for Genital Ulcers:

 



TREATMENT REGIMENS:

Syphilis

Chancroid

Benzathine penicillin, 2.4 million units i.m. after a proper sensitivity test
OR Tetracycline 500 mg orally 4 times a day x 15 days
OR Doxycycline 100 mg orally twice daily x 15 days
OR Erythromycin 500 mg orally four times a day x 15 days
Erythromycin 500 mg orally four times a day x 7 days.
OR Ciprofloxacin 500 mg single oral dose
OR Ceftrioxone 200 mg single i.m. dose
OR Spectinomycin 2g single i.m. dose
OR Co-trimoxazole Double Strength Orally twice daily x 7 days

Herpes 

Primary Genital Herpes

No known cure. Course of symptoms can be modified 
if diagnosed early and promptly treated with acyclovcir.

 

Acyclovir 200 mg orally 5 times a day x 7 days Recurrences: Advise to keep genital area clean by using saline washes, counsel and reassure about recurring lesions. Analgesics can be given for severe pain.

 

 

VAGINAL DISCHARGE  

go top

Most commonly caused by vaginitis but may also be the result of cervicitis. Common Causative organisms are N.gonorrhoeae and C. trachomatis(cervicitis),Trichomonas vaginalis, Candida albicans and synergistic combination of Gardnerella vaginalis and bacteria (vaginitis) Clinical differentiation between the two conditions is difficult.

Treatment of vaginitis 



Metronidazole 2g single oral dose under supervision or Metronidazole 400 mg given orally twice daily for 7 days plus NYSTATIN 100,000 units (one pessary) inserted intravaginally daily at night for l4 days or MICONAZOLE or CLOTRIMAZOLE 200 mg may be inserted into vagina daily for 3 days. or CLOTRIMAZOLE 500 mg is inserted into vagina once daily. Patient is advised to take the treatment and return in 14 days.

If the symptoms persist treat for cervicitis as follows:

CIPROFLOXACIN 500 mg in a single oral dose (under supervision) or NORFLOXACIN 800 mg single dose or CEFIXIME 400 single dose. CEFTRIAXONE 250 single IM dose or SPECTINOMYCIN in 2 gs in IM Dose Plus DOXYCYCLINE 100 mg orally twice daily for 7- 14 days for chlamdial infection or TETRACYCLINE 500 mg orally 4 times a day for 7 days or ERYTHROMYCIN 500 mg orally 4 times a day for 7 days.

 

 

LOWER ABDOMINAL PAIN ( LAP )

go top

 

LAP is often the presenting feature of women with pelvic inflammatory disease(PID) which is an infection of female genital tract above the internal os of the cervix and therefore means endometritis, salpingitis, tubo ovarian abscess and pelvic peritonitis. PID occurs as a result of ascending infection from the cervix and is caused by N. gonorrhoeae, C.trachomatis and anaerobic bacteria. The seriousness of PID lies in the fact that it can lead to pelvic peritonitis ovarian abscess and to generalised peritonitis which can be fatal illness. Blocked fallopian tubes following salpingitis could lead to subfertility or infertility.

Treatment: Remember that, in treating PID, treat simultaneously for gonococcal, chiamydial and anaerobic bacterial infections.

 

 

Treatment for Gonorrhea

 

CIPROFLOXACIN 500 mg single oral dose
OR NORFLOXACIN 800Mgsingleoraidose
OR CEFXIME 400 mg single oral dose
OR CEFTRIAXONE 250 mg single oral dose SPECTINOMYCIN 2 g single IM dose


 

PLUS Treatment for chlamydial infection

 

DOXYCYCLINE 100 mg orally twice daily for 14 days
OR TETRACYCLINE 500 mg orally four times daily for 14 days
OR ERYTHROMYCIN 500 mg orally four times daily for 10 days.


 

PLUS Treatment for anaerobic bacterial infection


METRONIDAZOLE 400 mg given orally twice daily for 14 days.

 

INIGUINAL BUBO

go top
 

Inguinal Bubo is acute suppurative inguinal lymphadenitis presenting as a painful swelling. A bubo can result from any kind of acute infection of the skin on the pubic area, genitals, buttocks, anus, thighs, legs, feet or toes. It may occur in STD such as chancroid and lymphogranuloma venerum(LGV). The enlarged inguinal lymph nodes, that are found in syphilis and HIV infection are not painful or tender to palpation and therefore can not be really be considered as bubos.

 

Treatment

 

If you find an inguinal bubo but no genital ulcer, treat the patient for LGV. A history of transient superficial ulcer is consistent with diagnosis of LGV. The treatment consists of Tetracycline 500 mg qid for 14 days. Alternatively Erythromycin 500 mg orally 4 times daily for 14 days.

A fluctuant bubo should be aspirated with a wide bore needle and syringe every second or third day until there is no aspirate. Under no circumstances should a bubo be incised.

 

 

ADVERSE DRUG RESISTANCE SCAN

go top

 

One of the most unusual adverse reactions known to be associated with fluroquinolone antibiotics is the occurrence of tendinitis. This is a serious effect since it may progress to tendon rupture with resultant disability. Over 2OO cases have been reported in the literature with the majority from France. Most members of the class including ciprofloxacin, enoxacin, ofloxacin, and norfloxacin have been implicated. The Achilles tendon is most often involved.

Adverse Drug Reactions Advisory Committee (ADRAC) of Australia has recorded 25 reports of tendinitis in association with norfloxacin. Most (22) have been with ciprofloxacin and the other three with norfloxacin. The majority of the patients involved were elderly. The daily dose of ciprofloxacin ranged from 750 mg to 2250 mg and for norfloxacin the usual daily dose of 800 mg. The average time of onset of reaction was within the first week. Almost all (23) of the reports specified Achilles tendon as the site of tendinitis. A number of risk factors have been identified with regard to this adverse reaction; these include age, renal dysfunction and concommitant corticosteroid therapy. Prescribers are reminded that tendinitis especially involving the Achilles tendon, is a rare adverse effect of the Fluoroquinolones. It is more likely to occur in association with the risk factors referred to above. The antibiotic should be withdrawn immediately to reduce the risk of tendon rupture.

 

 

 

DRUG POLICY ISSUES

go top
 

The role of any National Drug Policy is io use available resources to develop pharmaceutical services to meet the requirements of its citizens in prevention, diagnosis and treatment of diseases using efficacious high quality safe cost-effective pharmaceutical products. A National Drug Policy shall serve as the guide document for human resource planning and management.

 

Specific Objectives

go top

 

  1. To ensure constant availability of safe and effective drugs to all sectors of population.
  2. To provide drugs through the Government, private and Non-Government sectors at affordable prices.
  3. To facilitate Rational Drug Use through sound prescribing, good dispensing practices and appropriate usage.
  4. To ensure that the quality of drugs manufactured or imported into a country meet internationally accepted quality standards.
  5. To encourage self sufficiency through local manufacture of, drugs for consumption and export.

(Source: WHO, DAP and WOMEN HEALTH ACTION FOUNDATION PUBLICATIONS)